NASDAQ: THTXTheratechnologies Inc Stock
$2.82+0.12 (+4.44%)
Updated Apr 24, 2025
THTX Price
$2.82
Fair Value Price
N/A
Market Cap
$129.66M
52 Week Low
$1.08
52 Week High
$3.13
P/E
-50.36x
P/B
-7.58x
P/S
1.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$62.00M
Earnings
-$2.61M
Gross Margin
79%
Operating Margin
15.51%
Profit Margin
-4.2%
Debt to Equity
-3.31
Operating Cash Flow
-$4M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
THTX Overview
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine THTX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
THTX
Ranked#23 of 461
Ranked#23 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.94 | A | |
| $8.10 | A | |
| $23.19 | A |
Be the first to know about important THTX news, forecast changes, insider trades & much more!
THTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how THTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
THTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
THTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
THTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more THTX due diligence checks available for Premium users.
Valuation
THTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-50.36x
Industry
-333.97x
Market
26.39x
THTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-7.58x
Industry
4.33x
THTX's financial health
Profit margin
Revenue
$13.4M
Net Income
$82.4k
Profit Margin
0.6%
THTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
THTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$39.8M
Liabilities
$57.0M
Debt to equity
-3.31
THTX's short-term assets ($26.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THTX's long-term liabilities ($32.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
THTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.9M
Investing
-$4.9M
Financing
$3.3M
THTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
THTX vs Biotech Stocks
Theratechnologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.